When comparing weight loss across GLP-1 trials with routine care, check who had a follow-up weight. In this study, year-one measurements were sparse, especially for tirzepatide [1].
What the All of Us study measured
The cohort included 14,046 adults with obesity starting one of five drugs. The year-one analysis used recorded weights within 45 days of day 365 [1].
That window included 1,476 of 5,656 semaglutide starters (26.1%). Fewer than 20 of 386 tirzepatide starters had a weight in the window. The study reported a mean loss of 5.9% for semaglutide and 13.0% for tirzepatide.
Why the missing weights matter
Participants with a recorded weight may differ from those without one. The comparison used medical records without randomly assigning a drug. Differences in patients, treatment or follow-up could affect the estimates.
Access can affect whether a treatment plan is practical. In our knownwell review, the available visit formats illustrate one practical access consideration. The All of Us study did not compare providers or visit formats.
The researchers also estimated how quickly people reached 15% weight loss. Compared with liraglutide, adjusted hazard ratios were 1.77 for semaglutide and 5.57 for tirzepatide [1]. A hazard ratio measures relative rates over time.